MetaCap

Avalyn Pharma (AVLN) vs Nuvation Bio (NUVB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvation Bio is the larger company by market cap ($1.34 billion vs $1.26 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVLN-3.70%NUVB-14.61%
+67%+21%-25%
Apr 30, 20261 yearNov 20, 2026
AVLN-4.83%NUVB-15.37%
+58%+17%-24%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVLN versus NUVB key metrics
MetricAVLNNUVB
Share price$28.40$3.80
Market cap$1.26B$1.34B
1-day change-1.05%-0.26%
YTD return—-57.59%
1-year return—-45.64%
5-year return—-53.49%
EPS (TTM)$-3.96$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$62.90M
Revenue growth (YoY)—+698.96%
Net income (latest FY)—$-204.63M
Operating margin—-338.72%
Net margin—-325.31%
52-week high$40.17$9.75
52-week low$22.24$3.71
Distance from 52-week high-29.30%-61.03%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+114.79%+227.63%
Average volume352.95K5.24M
Shares outstanding44.52M352.02M
Employees56310
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalyn Pharma

AVLN stock →

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

AVLN vs NUVB FAQ

Which is bigger, Avalyn Pharma or Nuvation Bio?

Nuvation Bio (NUVB) is larger, with a market capitalization of $1.34B compared with $1.26B for Avalyn Pharma (AVLN).

Are Avalyn Pharma and Nuvation Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons